Search

Your search keyword '"Robillard, Nelly"' showing total 37 results
Start Over Author "Robillard, Nelly" Publication Year Range Last 10 years
37 results on '"Robillard, Nelly"'

2. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Author

Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G., Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C., Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, and Munshi, Nikhil

Published
2018
Full Text
View/download PDF

3. 90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

Author

Chevallier, Patrice, Eugene, Thomas, Robillard, Nelly, Isnard, Françoise, Nicolini, Franck, Escoffre-Barbe, Martine, Huguet, Françoise, Hunault, Mathilde, Marcais, Antoine, Gaschet, Joelle, Cherel, Michel, Guillaume, Thierry, Delaunay, Jacques, Peterlin, Pierre, Eveillard, Marion, Thomas, Xavier, Ifrah, Norbert, Lapusan, Simona, Bodet-Milin, Caroline, Barbet, Jacques, Faivre-Chauvet, Alain, Ferrer, Ludovic, Bene, Marie C, Le Houerou, Claire, Goldenberg, David M, Wegener, William A, and Kraeber-Bodéré, Françoise

Published
2015
Full Text
View/download PDF

7. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Author

Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Saint-Etienne, CHU UCL Namur, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), CHU Grenoble, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Montpellier (UM), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (MGD) Laboratoire de biologie clinique, UCL - (SLuc) Service d'hématologie, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)

Subjects
0301 basic medicine, Male, Cancer Research, Neoplasm, Residual, MESH: Immunotherapy, Chronic lymphocytic leukemia, Gastroenterology, MESH: Clinical Trials, Phase III as Topic, 0302 clinical medicine, Bone Marrow, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, MESH: Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Aged, education.field_of_study, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, MESH: Follow-Up Studies, Prognosis, 3. Good health, Fludarabine, Survival Rate, Leukemia, MESH: Antineoplastic Combined Chemotherapy Protocols, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, MESH: Vidarabine, MESH: Bone Marrow, Female, MESH: Rituximab, Immunotherapy, Rituximab, MESH: Clinical Trials, Phase II as Topic, Vidarabine, medicine.drug, medicine.medical_specialty, Cyclophosphamide, MESH: Survival Rate, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Chemoimmunotherapy, Internal medicine, medicine, Humans, education, Survival rate, MESH: Neoplasm, Residual, Aged, Retrospective Studies, MESH: Humans, business.industry, MESH: Cyclophosphamide, MESH: Retrospective Studies, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Male, body regions, 030104 developmental biology, Clinical Trials, Phase III as Topic, Bone marrow, business, MESH: Female, Follow-Up Studies
Abstract

International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD

Published
2020
Full Text
View/download PDF

8. Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma

Author

Debord, Camille, primary, Bourcier, Jessie, additional, Subiger, François, additional, Leclair, François, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Moreau, Anne, additional, Theisen, Olivier, additional, Godon, Catherine, additional, Robillard, Nelly, additional, Le Bris, Yannick, additional, Béné, Marie C, additional, and Wuillème, Soraya, additional

Published
2020
Full Text
View/download PDF

9. Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Département de pharmacie, Solly, Françoise, Angelot-Delettre, Fanny, Ticchioni, Michel, Geneviève, Franck, Rambaud, Hubert, Baseggio, Lucile, Plesa, Adriana, Debliquis, Agathe, Garnache-Ottou, Francine, Roggy, Anne, Campos, Lydia, Aanei, Carmen, Rosenthal-Allieri, Alessandra, Georget, Marie-Thérèse, Lachot, Sébastien, Jacob, Marie-Christine, Robillard, Nelly, Wuilleme, Soraya, Andre-Kerneis, Elisabeth, Cornet, Edouard, Salaun, Véronique, Bennami, Hind, Lhoumeau, Anne-Catherine, Arnoulet, Christine, JACQMIN, Hugues, NEYMAN, Nicolas, Latger-Cannard, Véronique, Massin, Fredéric, Lainey, Elodie, Le Garff-Tavernier, Magali, Costopoulos, Myrto, Roussel, Mickael, Mayeur-Rousse, Caroline, Eischen, Alice, Raggeneau, Victoria, Derrieux, Coralie, Maurer, Maxime, Asnafi, Vahid, Trinquand, Amélie, Brouzes, Chantal, Lhermitte, Ludovic, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Département de pharmacie, Solly, Françoise, Angelot-Delettre, Fanny, Ticchioni, Michel, Geneviève, Franck, Rambaud, Hubert, Baseggio, Lucile, Plesa, Adriana, Debliquis, Agathe, Garnache-Ottou, Francine, Roggy, Anne, Campos, Lydia, Aanei, Carmen, Rosenthal-Allieri, Alessandra, Georget, Marie-Thérèse, Lachot, Sébastien, Jacob, Marie-Christine, Robillard, Nelly, Wuilleme, Soraya, Andre-Kerneis, Elisabeth, Cornet, Edouard, Salaun, Véronique, Bennami, Hind, Lhoumeau, Anne-Catherine, Arnoulet, Christine, JACQMIN, Hugues, NEYMAN, Nicolas, Latger-Cannard, Véronique, Massin, Fredéric, Lainey, Elodie, Le Garff-Tavernier, Magali, Costopoulos, Myrto, Roussel, Mickael, Mayeur-Rousse, Caroline, Eischen, Alice, Raggeneau, Victoria, Derrieux, Coralie, Maurer, Maxime, Asnafi, Vahid, Trinquand, Amélie, Brouzes, Chantal, and Lhermitte, Ludovic

Abstract

Flow cytometry is broadly used for the identification, characterization, and monitoring of hematological malignancies. However, the use of clinical flow cytometry is restricted by its lack of reproducibility across multiple centers. Since 2006, the EuroFlow consortium has been developing a standardized procedure detailing the whole process from instrument settings to data analysis. The FranceFlow group was created in 2010 with the intention to educate participating centers in France about the standardized instrument setting protocol (SOP) developed by the EuroFlow consortium and to organise several rounds of quality controls (QCs) in order to evaluate the feasibility of its application and its results. Here, we report the 5 year experience of the FranceFlow group and the results of the seven QCs of 23 instruments, involving up to 19 centers, in France and in Belgium. The FranceFlow group demonstrates that both the distribution and applicability of the SOP have been successful. Intercenter reproducibility was evaluated using both normal and pathological blood samples. Coefficients of variation (CVs) across the centers were <7% for the percentages of cell subsets and <30% for the median fluorescence intensities (MFIs) of the markers tested. Intracenter reproducibility provided similar results with CVs of <3% for the percentages of the majority of cell subsets, and CVs of <20% for the MFI values for the majority of markers. Altogether, the FranceFlow group show that the 19 participating labs might be considered as one unique laboratory with 23 identical flow cytometers able to reproduce identical results. Therefore, SOP significantly improves reproducibility of clinical flow in hematology and opens new avenues by providing a robust companion diagnostic tool for clinical trials in hematology. © 2019 International Society for Advancement of Cytometry.

Published
2019

11. Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation

Author

LE Bris, Yannick, primary, Guillaume, Thierry, additional, Debord, Camille, additional, Peterlin, Pierre, additional, Wuilleme, Soraya, additional, Bressollette, Céline, additional, Le Bourgeois, Amandine, additional, Garnier, Alice, additional, Fantou, Aurélie, additional, Audrain, Marie, additional, Ménard, Audrey, additional, Robillard, Nelly, additional, Eveillard, Marion, additional, Le Gouill, Steven, additional, Imbert, Berthe Marie, additional, Bene, Marie C, additional, and Chevallier, Patrice, additional

Published
2019
Full Text
View/download PDF

12. FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia

Author

Peterlin, Pierre, primary, Gaschet, Joelle, additional, Guillaume, Thierry, additional, Garnier, Alice, additional, Eveillard, Marion, additional, Le Bourgeois, Amandine, additional, Cherel, Michel, additional, Debord, Camille, additional, Le Bris, Yannick, additional, Theisen, Olivier, additional, Mahé, Béatrice, additional, Dubruille, Viviane, additional, Godon, Catherine, additional, Robillard, Nelly, additional, Wuilleme, Soraya, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Blin, Nicolas, additional, Lok, Anne, additional, Bonnet, Antoine, additional, Le Gouill, Steven, additional, Moreau, Philippe, additional, Béné, Marie-C., additional, and Chevallier, Patrice, additional

Published
2019
Full Text
View/download PDF

13. Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience

Author

Solly, Françoise, primary, Angelot‐Delettre, Fanny, additional, Ticchioni, Michel, additional, Geneviève, Franck, additional, Rambaud, Hubert, additional, Baseggio, Lucile, additional, Plesa, Adriana, additional, Debliquis, Agathe, additional, Garnache‐Ottou, Francine, additional, Roggy, Anne, additional, Campos, Lydia, additional, Aanei, Carmen, additional, Rosenthal‐Allieri, Alessandra, additional, Georget, Marie‐Thérèse, additional, Lachot, Sébastien, additional, Jacob, Marie‐Christine, additional, Robillard, Nelly, additional, Wuilleme, Soraya, additional, Andre‐Kerneis, Elisabeth, additional, Cornet, Edouard, additional, Salaun, Véronique, additional, Bennami, Hind, additional, Lhoumeau, Anne‐Catherine, additional, Arnoulet, Christine, additional, Jacqmin, Hugues, additional, Neyman, Nicolas, additional, Latger‐Cannard, Véronique, additional, Massin, Fredéric, additional, Lainey, Elodie, additional, Le Garff‐Tavernier, Magali, additional, Costopoulos, Myrto, additional, Roussel, Mickael, additional, Mayeur‐Rousse, Caroline, additional, Eischen, Alice, additional, Raggeneau, Victoria, additional, Derrieux, Coralie, additional, Maurer, Maxime, additional, Asnafi, Vahid, additional, Trinquand, Amélie, additional, Brouzes, Chantal, additional, and Lhermitte, Ludovic, additional

Published
2019
Full Text
View/download PDF

14. FLT3 ligand plasma levels in acute myeloid leukemia

Author

Peterlin, Pierre, primary, Gaschet, Joelle, additional, Guillaume, Thierry, additional, Garnier, Alice, additional, Eveillard, Marion, additional, Le Bourgeois, Amandine, additional, Cherel, Michel, additional, Debord, Camille, additional, Le Bris, Yannick, additional, Theisen, Olivier, additional, Mahé, Béatrice, additional, Dubruille, Viviane, additional, Godon, Catherine, additional, Robillard, Nelly, additional, Wuilleme, Soraya, additional, Touzeau, Cyrille, additional, Gastinne, Thomas, additional, Blin, Nicolas, additional, Lok, Anne, additional, Bonnet, Antoine, additional, Le Gouill, Steven, additional, Moreau, Philippe, additional, Béné, Marie-C, additional, and Chevallier, Patrice, additional

Published
2019
Full Text
View/download PDF

15. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G, Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C, Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, Munshi, Nikhil, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G, Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C, Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, and Munshi, Nikhil

Abstract

The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. We assessed the prognostic value of MRD, measured during maintenance therapy by next-generation sequencing (NGS). MRD negativity was defined as the absence of tumor plasma cell within 1 000 000 bone marrow cells (<10). Data were analyzed from a recent clinical trial that evaluated the role of transplantation in newly diagnosed myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD). MRD negativity was achieved at least once during maintenance in 127 patients (25%). At the start of maintenance therapy, MRD was a strong prognostic factor for both progression-free survival (adjusted hazard ratio, 0.22; 95% confidence interval, 0.15-0.34; < .001) and overall survival (adjusted hazard ratio, 0.24; 95% confidence interval, 0.11-0.54; = .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.

Published
2018

16. Multicentric Standardized Flow Cytometry Routine Assessment of Patients With Sepsis to Predict Clinical Worsening

Author

Daix, Thomas, primary, Guerin, Estelle, additional, Tavernier, Elsa, additional, Mercier, Emmanuelle, additional, Gissot, Valérie, additional, Hérault, Olivier, additional, Mira, Jean-Paul, additional, Dumas, Florence, additional, Chapuis, Nicolas, additional, Guitton, Christophe, additional, Béné, Marie C., additional, Quenot, Jean-Pierre, additional, Tissier, Cindy, additional, Guy, Julien, additional, Piton, Gaël, additional, Roggy, Anne, additional, Muller, Grégoire, additional, Legac, Éric, additional, de Prost, Nicolas, additional, Khellaf, Mehdi, additional, Wagner-Ballon, Orianne, additional, Coudroy, Rémi, additional, Dindinaud, Elodie, additional, Uhel, Fabrice, additional, Roussel, Mikaël, additional, Lafon, Thomas, additional, Jeannet, Robin, additional, Vargas, Frédéric, additional, Fleureau, Catherine, additional, Roux, Mickaël, additional, Allou, Kaoutar, additional, Vignon, Philippe, additional, Feuillard, Jean, additional, François, Bruno, additional, Di Vittorio, Adollës, additional, Lachot, Sébastien, additional, Georget, Marie-Thérèse, additional, Hanna, Joelle, additional, Bretonnière, Cédric, additional, Zambon, Olivier, additional, Nicolet, Laurent, additional, Brule, Noëlle, additional, Debord, Camille, additional, Le Bris, Yannick, additional, Robillard, Nelly, additional, Dargent, Auguste, additional, Bretagnol, Anne, additional, Mathonnet, Armelle, additional, Boulain, Thierry, additional, Barbier, François, additional, Benzekri, Dalila, additional, Runge, Isabelle, additional, Kamel, Toufik, additional, Cecchini, Jérôme, additional, Bouyer, Sabrina, additional, Robert, René, additional, and Ouattara, Alexandre, additional

Published
2018
Full Text
View/download PDF

17. CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms

Author

Debord, Camille, primary, Robillard, Nelly, additional, Theisen, Olivier, additional, Gastinne, Thomas, additional, Godmer, Pascal, additional, Graveleau, Julie, additional, Le Gouill, Steven, additional, Luycx, Odile, additional, Tiab, Mourad, additional, Loirat, Marion, additional, Lestang, Elsa, additional, Wuillème, Soraya, additional, Godon, Catherine, additional, Eveillard, Marion, additional, and Béné, Marie Christine, additional

Published
2018
Full Text
View/download PDF

18. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Author

Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, and Cymbalista, Florence

Abstract

Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10−5) MRD assessment using flow cytometry, in blood (N= 401) and bone marrow (N= 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD < 0.01% to MRD ≥ 0.01% increased the proportion of cases with positive MRD in blood by 39% and in bone marrow by 27%. Compared to low-level positive MRD < 0.01%, undetectable MRD was associated with significantly longer progression-free survival (PFS) when using blood (72.2 versus 42.7 months; hazard ratio 0.40, p= 0.0003), but not when using bone marrow. Upon further stratification, positive blood MRD at any level, compared to undetectable blood MRD, was associated with shorter PFS irrespective of clinical complete or partial remission, and a lower 5-year PFS rate irrespective of IGHV-mutated or -unmutated status (all p< 0.05). In conclusion, high-sensitivity (0.0007%) MRD assessment in blood yielded additional prognostic information beyond the current standard sensitivity (0.01%). Our approach provides a model for future determination of the optimal MRD investigative strategy for any regimen.

Published
2021
Full Text
View/download PDF

19. Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia

Author

Chevallier, Patrice, primary, Chantepie, Sylvain, additional, Huguet, Francoise, additional, Raffoux, Emmanuel, additional, Thomas, Xavier, additional, Leguay, Thibaut, additional, Marchand, Tony, additional, Isnard, Francoise, additional, Charbonnier, Aude, additional, Maury, Sébastien, additional, Gallego-Hernanz, Maria-Pilar, additional, Robillard, Nelly, additional, Guillaume, Thierry, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Rialland, Fanny, additional, Le Houerou, Claire, additional, Goldenberg, David M., additional, Wegener, William A., additional, Béné, Marie-C., additional, and Dombret, Hervé, additional

Published
2017
Full Text
View/download PDF

20. ⁹⁰Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

Author

Chevallier, Patrice, Eugène, Thomas, Robillard, Nelly, Isnard, Françoise, Nicolini, Franck, Escoffre Barbe, Martine, Huguet, Françoise, Hunault, Mathilde, Marçais, Antoine, Gaschet, Joëlle, Cherel, Michel, Guillaume, Thierry, Delaunay, Jacques, Peterlin, Pierre, Eveillard, Marion, Thomas, Xavier, Ifrah, Norbert, Lapusan, Simona, Bodet-Milin, Caroline, Barbet, Jacques, Faivre-Chauvet, Alain, Ferrer, Ludovic, Bene, Marie, Le Houerou, Claire, Goldenberg, David, Wegener, William, Kraeber-Bodéré, Françoise, Bernardo, Elizabeth, Service d'Hématologie Clinique [Nantes], Hôpital Hôtel Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine Nucléaire [Nantes], Hôpital Laennec, Département d'hématologie et de biologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire d'Hématologie et d'Immunologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Pontchaillou [Rennes], Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'hématologie [Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Immunomedics Inc. [Morris Plains, NJ, USA], Laboratoire d'Hematologie [CHU Pontchaillou, Rennes] (Pôle de Biologie), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Service d'Hématologie [IUCT Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; Background: Prognosis of patients with relapsed or refractory acute lymphoblastic leukaemia is poor and new treatments are needed. We aimed to assess the feasibility, tolerability, dosimetry, and efficacy of yttrium-90-labelled anti-CD22 epratuzumab tetraxetan ((90)Y-DOTA-epratuzumab) radioimmunotherapy in refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia in a standard 3 + 3 phase 1 study.Methods: Adults (≥18 years) with relapsed or refractory B-cell acute lymphoblastic leukaemia (with CD22 expression on at least 70% of blast cells) were enrolled at six centres in France. Patients received one cycle of (90)Y-DOTA-epratuzumab on days 1 and 8 (give or take 2 days) successively at one of four dose levels: 2·5 mCi/m(2) (92·5 MBq/m(2); level 1), 5·0 mCi/m(2) (185 MBq/m(2); level 2), 7·5 mCi/m(2) (277·5 MBq/m(2); level 3), and 10·0 mCi/m(2) (370 MBq/m(2); level 4). The primary objective was to identify the maximum tolerated dose of (90)Y-DOTA-epratuzumab. We assessed safety during infusions and regularly after radioimmunotherapy over a 6-month period. Analyses included only patients who received radioimmunotherapy. The trial is closed to inclusion and is registered at ClinicalTrials.gov, NCT01354457.Findings: Between Aug 25, 2011, and June 11, 2014, 17 patients (median age 62 years; range 27-77) were treated (five at level 1, three at level 2, three at level 3, and six at level 4). Radioimmunotherapy infusion was overall well tolerated. One dose-limiting toxic effect (aplasia lasting 8 weeks) occurred at level 4, but the maximum tolerated dose was not reached. The most common grade 3-4 adverse events were pancytopenia (one patient at level 2, one at level 3, and six at level 4) and infections (three at level 1, one at level 2, and five at level 4).Interpretation: (90)Y-DOTA-epratuzumab radioimmunotherapy is well tolerated. We recommend the dose of 2 × 10·0 mCi/m(2) 1 week apart per cycle for phase 2 studies.Funding: Immunomedics and Direction de la Recherche Clinique of Nantes.

Published
2015
Full Text
View/download PDF

21. CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy

Author

Eveillard, Marion, primary, Floc'h, Victor, additional, Robillard, Nelly, additional, Debord, Camille, additional, Wuilleme, Soraya, additional, Garand, Richard, additional, Rialland, Fanny, additional, Thomas, Caroline, additional, Peterlin, Pierre, additional, Guillaume, Thierry, additional, Moreau, Philippe, additional, Chevallier, Patrice, additional, and Bene, Marie C, additional

Published
2016
Full Text
View/download PDF

22. In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)

Author

Clemenceau, Beatrice, primary, Guillaume, Thierry, additional, Robillard, Nelly, additional, Vivien, Regine, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Bene, Marie-Christine, additional, Vié, Henri, additional, and Chevallier, Patrice, additional

Published
2016
Full Text
View/download PDF

23. Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

Author

Chevallier, Patrice, primary, Chantepie, Sylvain, additional, Huguet, Françoise, additional, Raffoux, Emmanuel, additional, Thomas, Xavier, additional, Leguay, Thibaut, additional, Marchand, Tony, additional, Isnard, Francoise, additional, Charbonnier, Aude, additional, Maury, Sebastien, additional, Gallego-Hernanz, Maria-Pilar, additional, Robillard, Nelly, additional, Guillaume, Thierry, additional, Peterlin, Pierre, additional, Garnier, Alice, additional, Rialland, Fanny, additional, Le Houerou, Claire, additional, Goldenberg, David M, additional, Wegener, William, additional, Bene, Marie C, additional, and Dombret, Herve, additional

Published
2016
Full Text
View/download PDF

24. A new mutation of ANO6 in two familial cases of Scott syndrome

Author

Boisseau, Pierre, primary, Bene, Marie C., additional, Besnard, Thomas, additional, Pachchek, Sinthuja, additional, Giraud, Mathilde, additional, Talarmain, Patricia, additional, Robillard, Nelly, additional, Gourlaouen, Marie A., additional, Bezieau, Stéphane, additional, and Fouassier, Marc, additional

Published
2016
Full Text
View/download PDF

25. Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

Author

Avet-Loiseau, Herve, primary, Corre, Jill, additional, Lauwers-Cances, Valerie, additional, Chretien, Marie-Lorraine, additional, Robillard, Nelly, additional, Leleu, Xavier, additional, Hulin, Cyrille, additional, Gentil, Catherine, additional, Arnulf, Bertrand, additional, Belhadj, Karim, additional, Brechignac, Sabine, additional, Garderet, Laurent, additional, Karlin, Lionel, additional, Marit, Gerald, additional, Benboubker, Lotfi, additional, Orsini-Piocelle, Frederique, additional, Royer, Bruno, additional, Drenou, Bernard, additional, Tiab, Mourad, additional, Lamy, Thierry, additional, MACRO, Margaret, additional, Richardson, Paul G., additional, Anderson, Kenneth C, additional, Faham, Malek, additional, Facon, Thierry, additional, Moreau, Philippe, additional, Attal, Michel, additional, and Munshi, Nikhil C., additional

Published
2015
Full Text
View/download PDF

26. Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome

Author

Le Bris, Yannick, primary, Guillaume, Thierry, additional, Iliaquer, Marina, additional, Martin, Jerome, additional, Peterlin, Pierre, additional, Menard, Audrey, additional, Eveillard, Marion, additional, Wuilleme, Soraya, additional, Robillard, Nelly, additional, Delaunay, Jacques, additional, Mohty, Mohamad, additional, Garnier, Alice, additional, Moreau, Philippe, additional, Bene, Marie C, additional, and Chevallier, Patrice, additional

Published
2015
Full Text
View/download PDF

27. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia

Author

Eveillard, Marion, primary, Robillard, Nelly, additional, Arnoux, Isabelle, additional, Garand, Richard, additional, Rialland, Fanny, additional, Thomas, Caroline, additional, Strullu, Marion, additional, Michel, Gérard, additional, Béné, Marie C., additional, Fossat, Chantal, additional, and Loosveld, Marie, additional

Published
2015
Full Text
View/download PDF

28. 90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

Author

Chevallier, Patrice, primary, Eugene, Thomas, additional, Robillard, Nelly, additional, Isnard, Françoise, additional, Nicolini, Franck, additional, Escoffre-Barbe, Martine, additional, Huguet, Françoise, additional, Hunault, Mathilde, additional, Marcais, Antoine, additional, Gaschet, Joelle, additional, Cherel, Michel, additional, Guillaume, Thierry, additional, Delaunay, Jacques, additional, Peterlin, Pierre, additional, Eveillard, Marion, additional, Thomas, Xavier, additional, Ifrah, Norbert, additional, Lapusan, Simona, additional, Bodet-Milin, Caroline, additional, Barbet, Jacques, additional, Faivre-Chauvet, Alain, additional, Ferrer, Ludovic, additional, Bene, Marie C, additional, Le Houerou, Claire, additional, Goldenberg, David M, additional, Wegener, William A, additional, and Kraeber-Bodéré, Françoise, additional

Published
2015
Full Text
View/download PDF

29. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.

Author

Eveillard, Marion, Robillard, Nelly, Arnoux, Isabelle, Garand, Richard, Rialland, Fanny, Thomas, Caroline, Strullu, Marion, Michel, Gérard, Béné, Marie C., Fossat, Chantal, and Loosveld, Marie

Subjects
LYMPHOBLASTIC leukemia diagnosis, CARCINOGENESIS, BONE marrow, FLOW cytometry, LYMPHOBLASTIC leukemia
Abstract

The early persistence of minimal residual disease (MRD) is considered a poor prognostic factor indicative of chemoresistance in acute lymphoblastic leukemia. In French children, chemosensitivity is assessed at day 21 post-induction by cytomorphology. Here, it was investigated whether a more precise evaluation could be obtained at this time point with multiparameter flow cytometry (MFC). This study enrolled 123 children with de novo acute lymphoblastic leukemia. MRD0 was investigated at day 21 in MFC with a combination of antibodies based on the immunophenotype of diagnosis. It was also evaluated at day 35 by immunoglobulin/T-cell receptor quantitative real-time polymerase chain reaction (MRD1). Three risk groups could be delineated based on MRD0. Patients with MFC/MRD0 levels >10-2 (n = 25) were considered high risk, those with levels between 10-2 and 10-4 (n = 46) intermediate risk, and those <10-4 (n = 50) low risk. Overall survival (p = 0.048) and event-free survival (EFS, p = 0.00017) were significantly different between these three groups. EFS of the 14 corticoresistant patients strongly depended on their MRD0 level (p = 0.004). Similarly, both EFS (p = 0.0004) and overall survival (p = 0.02) were significantly different in the 109 chemosensitive patients, according to MRD0 levels. MRD0 and MRD1 levels, compared with 112 patients, were consistent (-/- or +/+) in 57.2% of the cases. Both MRD0+/MRD1+ and MRD0+/MRD1- patients had a significantly worse EFS (p = 0.0001) than those with undetectable MRD at both MRD0 and MRD1. This study confirms the usefulness and superiority of an early point of MRD detection by MFC. In addition, MRD0 in MFC identifies a subgroup of patients with poorer prognosis (MRD0+/MRD1-). Copyright © 2015 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

30. Phase 1 Dose-Escalation Study of 90yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Author

Chevallier, Patrice, primary, Eugene, Thomas, additional, Robillard, Nelly, additional, Isnard, Françoise, additional, Nicolini, Franck E, additional, Escoffre-Barbe, Martine, additional, Huguet, Françoise, additional, Hunault, Mathilde, additional, Marcais, Antoine, additional, Guillaume, Thierry, additional, Delaunay, Jacques, additional, Peterlin, Pierre, additional, Thomas, Xavier, additional, Ifrah, Norbert, additional, Lapusan, Simona, additional, bodet-Milin, Caroline, additional, faivre Chauvet, Alain, additional, Le Houerou, Claire, additional, Goldenberg, David M, additional, Wegener, William A, additional, and Kraeber-Bodere, Françoise, additional

Published
2014
Full Text
View/download PDF

31. Value of Day 21 Flow Cytometry Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia (ALL) for Early Identification of Good Responders

Author

Eveillard, Marion, primary, Robillard, Nelly, additional, Garand, Richard, additional, Rialland, Fanny, additional, Blin, Nicolas, additional, Strullu, Marion, additional, Thomas, Caroline, additional, Fossat, Chantal, additional, Arnoux, Isabelle, additional, Bene, Marie-Christine, additional, and Loosveld, Marie, additional

Published
2014
Full Text
View/download PDF

32. Chemoimmunotherapy Combining Vincristine, Dexamethasone and Epratuzumab (hLL2) As Salvage Regimen for Older Relapsed/Refractory, CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) Patients: Results of the French Non-Intensive Phase 2 Prospective Cheprall Study

Author

Chevallier, Patrice, primary, Huguet, Françoise, additional, Raffoux, Emmanuel, additional, Etienne, Anne, additional, Leguay, Thibaut, additional, Isnard, Françoise, additional, Robillard, Nelly, additional, Guillaume, Thierry, additional, Delaunay, Jacques, additional, Peterlin, Pierre, additional, Charbonnier, Aude, additional, Pigneux, Arnaud, additional, Le Houerou, Claire, additional, Goldenberg, David M, additional, Wegener, William A, additional, and Dombret, Hervé, additional

Published
2014
Full Text
View/download PDF

33. CD180 Expression in B-Cell Lymphomas: A Multicenter Geil Study

Author

Mayeur-Rousse, Caroline, primary, Guy, Julien, additional, Miguet, Laurent, additional, Bouyer, Sabrina, additional, Genevieve, Franck, additional, Robillard, Nelly, additional, Solly, Francoise, additional, Maar, Aida, additional, Bene, Marie-C, additional, and Mauvieux, Laurent, additional

Published
2014
Full Text
View/download PDF

35. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A french multicenter study.

Author

Fossat, Chantal, Roussel, Mikael, Arnoux, Isabelle, Asnafi, Vahid, Brouzes, Chantal, Garnache‐Ottou, Francine, Jacob, Marie‐Christine, Kuhlein, Emilienne, Macintyre‐Davi, Elizabeth, Plesa, Adriana, Robillard, Nelly, Tkaczuk, Jean, Ifrah, Norbert, Dombret, Herve, Béné, Marie C., Baruchel, Andre, and Garand, Richard

Published
2015
Full Text
View/download PDF

36. Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study

Author

Roussel, Murielle, Lauwers-Cances, Valerie, Robillard, Nelly, Belhadj, Karim, Facon, Thierry, Garderet, Laurent, Escoffre, Martine, Pegourie, Brigitte, Benboubker, Lotfi, Caillot, Denis, Fohrer, Cecile, Moreau, Philippe, Leleu, Xavier, Avet-Loiseau, Herve, and Attal, Michel

Abstract

Roussel: BMS: Other: lecture fees; sanofi: Other: lecture fees; AMGEN: Consultancy, Other: lecture fees, Research Funding; celgene: Consultancy, Other: lecture fees, Research Funding; janssen: Consultancy, Other: lecture fees. Belhadj:janssen: Consultancy; novartis: Consultancy. Facon:celgene: Consultancy; janssen: Consultancy; sanofi: Consultancy; BMS: Consultancy; novartis: Consultancy; amgen: Consultancy. Garderet:Novartis: Consultancy; Takeda: Consultancy; Amgen: Consultancy; BMS: Consultancy, Honoraria. Fohrer:celgne: Consultancy; amgen: Consultancy. Moreau:Janssen: Honoraria, Speakers Bureau; Bristol-Myers Squibb: Honoraria; Amgen: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Celgene: Honoraria. Leleu:TEVA: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; LeoPharma: Honoraria; Pierre Fabre: Honoraria; Amgen: Honoraria; Bristol-Myers Squibb: Honoraria; Takeda: Honoraria; Celgene: Honoraria; Janssen: Honoraria. Avet-Loiseau:celgene: Consultancy; amgen: Consultancy; sanofi: Consultancy; janssen: Consultancy. Attal:amgen: Consultancy, Research Funding; celgene: Consultancy, Research Funding; janssen: Consultancy, Research Funding; sanofi: Consultancy.

Published
2016
Full Text
View/download PDF

37. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

Author

Chevallier P, Huguet F, Raffoux E, Etienne A, Leguay T, Isnard F, Robillard N, Guillaume T, Delaunay J, Charbonnier A, Pigneux A, Peterlin P, Bené MC, Wegener WA, Goldenberg DM, and Dombret H

Subjects
Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Dexamethasone administration & dosage, Humans, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma mortality, Recurrence, Sialic Acid Binding Ig-like Lectin 2 metabolism, Treatment Outcome, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results